Overview

Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.

Status:
Completed

Trial end date:
2019-01-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical study is to determine the efficacy and safety of Seviteronel, a lyase-selective inhibitor of CYP17 and an androgen receptor antagonist, in patients with castration-resistant prostate cancer (CRPC) who have been previously treated with enzalutamide and/or abiraterone.

Phase:

Phase 2

Details

Lead Sponsor:

Innocrin Pharmaceutical

Collaborators:

Prostate Cancer Clinical Trials Consortium
Prostate Cancer Foundation

Treatments:

Seviteronel